2024年5月20日 · Multidrug-resistant TB (MDR-TB) is a form of TB disease caused by a strain of M. tuberculosis complex that is resistant to rifampicin and isoniazid. Globally, an estimated 410 000 people (95% UI: 370 000–450 000) developed multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) in 2022.

2023年12月21日 · There are different types of drug-resistant TB disease, depending on what medicines the TB germs are resistant to. Multidrug-resistant TB disease (MDR TB) is caused by germs that are resistant to two or more of the main TB medicines: isoniazid and rifampin.

为更好地推广和实践WHO制定的"MDR-TB和RR-TB治疗指南（2018更新版）"和"耐药结核病治疗指南（整合版）"，提高我国广大结核病防治工作者对MDR-TB和RR-TB的诊治水平，中华医学会结核病学分会组织结核病领域的专家，结合我国的实际情况，制定了"中国耐多药和利福平耐药结核病治疗专家共识（2019年版）"，供国内同道借鉴。 本共识采用WHO推荐的证据质量分级和推荐强度系统（简称GRADE系统）对推荐意见的级别（表1）和循证医学证据的质量（表2）进行评估 …

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin.

2025年1月6日 · Drug-resistant tuberculosis (TB) disease is caused by TB bacteria that are resistant to at least one of the most effective TB medicines used in treatment regimens. Drug-resistant TB is transmitted in the same way as drug-susceptible TB.

耐多药结核病（mdr-tb）是一种由对利福平和异烟肼具有耐药性的结核分枝杆菌复合群菌株引起的结核病。 2022年，全球估计有41万人（95%置信区间：37万 - 45万）患有耐多药结核病或利福平耐药结核病。

2024年3月24日 · Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in...

Extensively drug-resistant (XDR) TB refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs. The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities.

WHO发表了首次全球范围内多重耐药结核菌（MDR-TB）感染的总体评估，调查显示，2004年全球MDR-TB感染患者估计共424203例，9个独立变量可能与结核菌多重耐药相关。 [J Infect Dis 2006,194 (4):479] MDR-TB是结核病控制面临的巨大挑战。 自1994年出台抗结核杆菌耐药全球计划以来，WHO已经收集了90个国家的结核杆菌耐药资料。 2000年全球感染MDR-TB的患者估计 …

Globally, MDR/RR-TB caused an estimated 150 000 (95% UI: 94 000–210 000) deaths in 2023. The reason why the number of people developing MDR/RR-TB is not estimated to have increased from 2020–2023, in contrast to the number of people developing TB overall (Section 1.1), is that increases in the overall number of people developing TB have been offset by an estimated downward trend since 2015 ...